Table 3.
MR estimates examining the association of genetically proxied perturbation of ABCC8 with site-specific and overall cancer risk
| Outcome | N (cases; controls) | OR (95% CI) | p value |
|---|---|---|---|
| Breast cancer | 122,977; 105,974 | 2.09 (0.81, 5.39) | 0.13 |
| ER+ breast cancer | 69,501; 105,974 | 2.10 (0.66, 6.74) | 0.21 |
| ER− breast cancer | 21,468; 105,974 | 1.83 (0.48, 6.97) | 0.38 |
| Colorectal cancer | 58,221; 67,694 | 0.61 (0.21, 1.76) | 0.36 |
| Colon cancer | 32,002; 64,159 | 0.55 (0.15, 1.93) | 0.35 |
| Rectal cancer | 16,212; 64,159 | 0.76 (0.15, 3.87) | 0.74 |
| Prostate cancer | 79,148; 61,106 | 0.94 (0.37, 2.43) | 0.91 |
| Advanced prostate cancera | 15,167; 58,308 | 1.67 (0.32, 8.57) | 0.54 |
| Overall cancer risk | 27,483; 372,016 | 0.90 (0.31, 2.59) | 0.85 |
ORs (95% CIs) are scaled to represent the effect of genetically proxied perturbation of ABCC8 equivalent to a 1 unit lowering of IRNT HbA1c (mmol/mol)
aAdvanced prostate cancer is defined as metastatic disease, Gleason score ≥8, prostate-specific antigen >100 or prostate cancer-related death